Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Mar 8;76(10):929-30.
doi: 10.1212/WNL.0b013e31820f2d94.

Rituximab monotherapy for patients with recurrent primary CNS lymphoma

T T Batchelor  1 , S A Grossman, T Mikkelsen, X Ye, S Desideri, G J Lesser
Affiliations
Clinical Trial

Rituximab monotherapy for patients with recurrent primary CNS lymphoma

T T Batchelor et al. Neurology. .
No abstract available

PubMed Disclaimer

References

    1. Shah G, Yahalom J, Correa D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730–4735 - PubMed
    1. Enting R, Demopoulos A, DeAngelis L, Abrey L. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901–903 - PubMed
    1. Rubenstein JL, Rosenberg J, Damon L. High-dose methotrexate plus rituximab (Anti-CD20) monoclonal antibody in the treatment of primary CNS lymphoma. Society for Neuro-Oncology fourth annual meeting, Scottsdale, AZ, November 17–21, 1999 Abstract
    1. Dietlein M, Pels H, Schulz H, et al. Imaging of central nervous system lymphomas with I123-labeled rituximab. Eur J Haematol 2005;74:348–352 - PubMed
    1. Maza S, Kiewe P, Munz DL, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neurooncol 2009;11:423–429 - PMC - PubMed

Publication types

Substances